Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00604175 · ClinicalTrials.gov registry record · Phase 2
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase 2 study of HIV Infections and Sexually Transmitted Diseases, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 319
- Enrollment target
- 20
- Study locations
NCT00604175 is a Phase 2 study of HIV Infections and Sexually Transmitted Diseases that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 319 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00604175, a Phase 2 study of HIV Infections and Sexually Transmitted Diseases, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 319 participants
- Enrollment target
- 20
- Study locations
Study Summary
Human papillomavirus (HPV) is the most common sexually transmitted disease in the world. HPV infection can cause genital warts and certain cervical problems, including cervical cancer. HPV infection may be more severe and harder to treat in HIV-infected people. The purpose of this study was to determine whether the quadrivalent HPV vaccine is safe, tolerable, and effective in producing antibodies to HPV in HIV-infected women.
Conditions Studied
Interventions
- BIOLOGICAL Quadrivalent HPV vaccine
Study Locations (20)
California
- Usc La Nichd Crs - Alhambra
- University of California, UC San Diego CRS - La Jolla
- Miller Children's Hosp. Long Beach CA NICHD CRS - Long Beach
- University of Southern California CRS - Los Angeles
- UCLA CARE Center CRS - Los Angeles
- Stanford AIDS Clinical Trials Unit CRS - Palo Alto
- UCSD Antiviral Research Center CRS - San Diego
- Ucsf Hiv/Aids Crs - San Francisco
Florida
- South Florida CDTC Ft Lauderdale NICHD CRS - Fort Lauderdale
- Univ. of Florida Jacksonville NICHD CRS - Jacksonville
- Pediatric Perinatal HIV Clinical Trials Unit CRS - Miami
- The University of Miami AIDS Clinical Research Unit (ACRU) CRS - Miami
Colorado
- University of Colorado Hospital CRS - Aurora
- Denver Public Health CRS - Denver
District of Columbia
- Georgetown University CRS (GU CRS) - Washington D.C.
- Howard Univ. Washington DC NICHD CRS - Washington D.C.
Illinois
- Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program - Chicago
- Northwestern University CRS - Chicago
Alabama
- Alabama Therapeutics CRS - Birmingham
Georgia
- The Ponce de Leon Center CRS - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 319 participants |
| Start Date | 2008-02 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00604175
The ClinicalTrials.gov registry entry for NCT00604175 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 319 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (28% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Quadrivalent HPV vaccine is the first listed.
NCT00604175 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00604175 about?
NCT00604175 is a clinical study titled "Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women". Human papillomavirus (HPV) is the most common sexually transmitted disease in the world. HPV infection can cause genital warts and certain cervical problems, including cervical cancer. HPV infection may be more severe and harder to treat in HIV-infected people. The purpose of this study was to deter...
What is the current status of trial NCT00604175?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 319 participants. The study started on 2008-02. Estimated completion is 2012-11.
What conditions does trial NCT00604175 study?
This clinical trial studies the following conditions: HIV Infections, Sexually Transmitted Diseases.
What interventions are being tested in trial NCT00604175?
The interventions under investigation include: Quadrivalent HPV vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00604175?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00604175 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.